Bianchetti Lucrezia, Walker Anna, Marchal Ophelie, Bruschi Laura, Wüthrich Héloïse, Goossens An, Dendooven Ella, Aerts Olivier, Conrad Curdin, Gilliet Michel, Seremet Teofila
Department of Dermatology and Venereology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Faculty of Medicine, KU Leuven, Leuven, Belgium.
Contact Dermatitis. 2025 Oct;93(4):328-335. doi: 10.1111/cod.14838. Epub 2025 Jul 7.
Surgical glues are increasingly used, offering advantages like reduced scarring and faster wound closure. However, they pose risks of localised and disseminated allergic contact dermatitis caused by cyanoacrylate monomers.
This study aims to evaluate sensitisation patterns to cyanoacrylate-based surgical glues, the usefulness of testing with the commercially available ethyl cyanoacrylate, and cross-reactions between cyanoacrylates and (meth)acrylates.
PATIENTS/METHODS: Sixteen patients with suspected allergic contact dermatitis (ACD) from surgical adhesives were patch tested with the European Standard and Acrylate series (only containing ethyl cyanoacrylate) among other series, of whom 15 were tested with the surgical glues used. Clinical data, including demographics and surgical histories, were collected.
Fifteen patients (94%) tested positively to surgical glues, with 81% showing positive reactions to ethyl cyanoacrylate, to which the patient not tested to the glue "as is" also reacted. Three ethyl cyanoacrylate-negative patients reacted to Dermabond Prineo. Exclusive sensitisation to ethyl cyanoacrylate was observed in eight patients, while five reacted to other (meth)acrylic compounds.
Ethyl cyanoacrylate is a screening agent for surgical-glue sensitised patients, but if negative, tape-stripping-modified patch testing, also with the glues, is indicated. Cross-reactions can occur between cyanoacrylates and co-reactions (concomitant sensitization) with certain (meth)acrylates. Primary sensitisation is particularly relevant in patients undergoing treatment with cyanoacrylate-based glues for the first time, rather than because of previous exposure to other sources.
手术胶水的使用越来越广泛，具有减少疤痕形成和加快伤口愈合等优点。然而，它们会引发由氰基丙烯酸酯单体导致的局部和播散性过敏性接触性皮炎风险。
本研究旨在评估对氰基丙烯酸酯基手术胶水的致敏模式、使用市售氰基丙烯酸乙酯进行检测的效用，以及氰基丙烯酸酯与（甲基）丙烯酸酯之间的交叉反应。
患者/方法：16例疑似手术胶粘剂过敏性接触性皮炎（ACD）的患者接受了欧洲标准系列和丙烯酸酯系列（仅含氰基丙烯酸乙酯）以及其他系列的斑贴试验，其中15例患者接受了所使用手术胶水的检测。收集了包括人口统计学和手术史在内的临床数据。
15例患者（94%）对手术胶水检测呈阳性，81%对氰基丙烯酸乙酯呈阳性反应，未对“原样”胶水进行检测的患者也对其有反应。3例氰基丙烯酸乙酯阴性患者对德玛邦普瑞尼奥有反应。8例患者观察到对氰基丙烯酸乙酯的单纯致敏，而5例对其他（甲基）丙烯酸化合物有反应。
氰基丙烯酸乙酯是手术胶水致敏患者的筛查剂，但如果结果为阴性，则建议进行胶带剥离改良斑贴试验，也使用胶水进行检测。氰基丙烯酸酯之间可能发生交叉反应，以及与某些（甲基）丙烯酸酯发生共反应（伴随致敏）。初次致敏在首次接受氰基丙烯酸酯基胶水治疗的患者中尤为相关，而非由于先前接触其他来源。
